Literature DB >> 12192085

Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

Bryan L Roth1, Karen Baner, Richard Westkaemper, Daniel Siebert, Kenner C Rice, SeAnna Steinberg, Paul Ernsberger, Richard B Rothman.   

Abstract

Salvia divinorum, whose main active ingredient is the neoclerodane diterpene Salvinorin A, is a hallucinogenic plant in the mint family that has been used in traditional spiritual practices for its psychoactive properties by the Mazatecs of Oaxaca, Mexico. More recently, S. divinorum extracts and Salvinorin A have become more widely used in the U.S. as legal hallucinogens. We discovered that Salvinorin A potently and selectively inhibited (3)H-bremazocine binding to cloned kappa opioid receptors. Salvinorin A had no significant activity against a battery of 50 receptors, transporters, and ion channels and showed a distinctive profile compared with the prototypic hallucinogen lysergic acid diethylamide. Functional studies demonstrated that Salvinorin A is a potent kappa opioid agonist at cloned kappa opioid receptors expressed in human embryonic kidney-293 cells and at native kappa opioid receptors expressed in guinea pig brain. Importantly, Salvinorin A had no actions at the 5-HT(2A) serotonin receptor, the principal molecular target responsible for the actions of classical hallucinogens. Salvinorin A thus represents, to our knowledge, the first naturally occurring nonnitrogenous opioid-receptor subtype-selective agonist. Because Salvinorin A is a psychotomimetic selective for kappa opioid receptors, kappa opioid-selective antagonists may represent novel psychotherapeutic compounds for diseases manifested by perceptual distortions (e.g., schizophrenia, dementia, and bipolar disorders). Additionally, these results suggest that kappa opioid receptors play a prominent role in the modulation of human perception.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12192085      PMCID: PMC129372          DOI: 10.1073/pnas.182234399

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Dynorphin-(1-13), an extraordinarily potent opioid peptide.

Authors:  A Goldstein; S Tachibana; L I Lowney; M Hunkapiller; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

2.  Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6.

Authors:  David A Shapiro; Kurt Kristiansen; David M Weiner; Wesley K Kroeze; Bryan L Roth
Journal:  J Biol Chem       Date:  2002-01-18       Impact factor: 5.157

3.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

4.  Relative contents and concomitant release of prodynorphin/neoendorphin-derived peptides in rat hippocampus.

Authors:  C Chavkin; C Bakhit; E Weber; F E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

5.  Dynorphin is contained within hippocampal mossy fibers: immunochemical alterations after kainic acid administration and colchicine-induced neurotoxicity.

Authors:  J F McGinty; S J Henriksen; A Goldstein; L Terenius; F E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

6.  Dynorphin is a specific endogenous ligand of the kappa opioid receptor.

Authors:  C Chavkin; I F James; A Goldstein
Journal:  Science       Date:  1982-01-22       Impact factor: 47.728

7.  The distribution and morphology of opioid peptide immunoreactive neurons in the cerebral cortex of rats.

Authors:  J F McGinty; D van der Kooy; F E Bloom
Journal:  J Neurosci       Date:  1984-04       Impact factor: 6.167

8.  Ontogeny of benzomorphan-selective (kappa) sites: a computerized analysis.

Authors:  J W Spain; D B Bennett; B L Roth; C J Coscia
Journal:  Life Sci       Date:  1983       Impact factor: 5.037

9.  Novel opiate binding sites selective for benzomorphan drugs.

Authors:  K J Chang; E Hazum; P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

10.  Characterization of the kappa-subtype of the opiate receptor in the guinea-pig brain.

Authors:  H W Kosterlitz; S J Paterson; L E Robson
Journal:  Br J Pharmacol       Date:  1981-08       Impact factor: 8.739

View more
  248 in total

1.  Salvinorin A pretreatment preserves cerebrovascular autoregulation after brain hypoxic/ischemic injury via extracellular signal-regulated kinase/mitogen-activated protein kinase in piglets.

Authors:  Diansan Su; John Riley; William M Armstead; Renyu Liu
Journal:  Anesth Analg       Date:  2011-11-10       Impact factor: 5.108

Review 2.  Hallucinogens: an update.

Authors:  John H Halpern
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

3.  Hallucinogen actions on human brain revealed.

Authors:  Hyeong-Min Lee; Bryan L Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

4.  Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.

Authors:  Eduardo R Butelman; Michael Caspers; Kimberly M Lovell; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  J Pharmacol Exp Ther       Date:  2012-03-20       Impact factor: 4.030

Review 5.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 6.  Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins.

Authors:  Yingxue Li; Mark R Lefever; Dhanasekaran Muthu; Jean M Bidlack; Edward J Bilsky; Robin Polt
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

7.  N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a Novel Class of Selective, Nonbasic, Nitrogen-Containing κ-Opioid Receptor Ligands.

Authors:  Kevin J Frankowski; Partha Ghosh; Vincent Setola; Thuy B Tran; Bryan L Roth; Jeffrey Aubé
Journal:  ACS Med Chem Lett       Date:  2010-08-12       Impact factor: 4.345

8.  Biosynthesis of salvinorin A proceeds via the deoxyxylulose phosphate pathway.

Authors:  Lukasz Kutrzeba; Franck E Dayan; J'Lynn Howell; Ju Feng; José-Luis Giner; Jordan K Zjawiony
Journal:  Phytochemistry       Date:  2007-06-14       Impact factor: 4.072

9.  Localization of salvinorin A and related compounds in glandular trichomes of the psychoactive sage, Salvia divinorum.

Authors:  Daniel J Siebert
Journal:  Ann Bot       Date:  2004-04-15       Impact factor: 4.357

10.  Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.

Authors:  Thomas A Munro; Katharine K Duncan; Wei Xu; Yulin Wang; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen; Cécile Béguin
Journal:  Bioorg Med Chem       Date:  2007-10-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.